NanoMedicine Labs
NanoMedicine Labs Raises $460M Series C to Transform Healthcare
Quick Facts
NanoMedicine Labs
Breakthrough nanoscale drug delivery systems enabling targeted cancer treatment with 95% reduced side effects.
About the Funding
NanoMedicine Labs has successfully raised $460M in a Series C funding round, bringing their total valuation to $5.8B. This significant investment will fuel the company's mission to advance phase iii clinical trials, scale manufacturing capabilities, and expand pipeline to rare diseases.
Use of Funds
Advance Phase III clinical trials, scale manufacturing capabilities, and expand pipeline to rare diseases
Company Overview
Breakthrough nanoscale drug delivery systems enabling targeted cancer treatment with 95% reduced side effects.
Key Investors
- • Johnson & Johnson Innovation
- • Roche Ventures
- • RA Capital
- • Flagship Pioneering
Founders
- • Dr. Jennifer Liu
- • Dr. Robert Kim
Previous Rounds
Market Impact
This funding round positions NanoMedicine Labs as a leader in the Biotech space, with the capital to accelerate innovation and expand their market presence. The investment reflects growing confidence in healthcare solutions and the company's potential to transform the industry.
Key Investors
About the Author
Related Company Reports
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza